STUDY OF IN VIVO IMMUNOMODULATION BY INDOMETHACIN IN ACQUIRED IMMUNE DEFICIENCY SYNDROME AND AIDS-RELATED COMPLEX

Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

STUDY OF IN VIVO IMMUNOMODULATION BY INDOMETHACIN IN ACQUIRED IMMUNE DEFICIENCY SYNDROME AND AIDS-RELATED COMPLEX

Int J Immunotherapy; 2(4):295-300 1986. Unique Identifier : AIDSLINE ICDB/88639939
Grieco MH; Reddy MM; Moriarty ML; Manvar D; Ahuja KK; Bellomo S; Holtz H; Dobro J; Keslak JW; Cohen E; et al; R.A. Cooke Inst. of Allergy, St. Luke's/Roosevelt Hosp. Center,; New York, NY

Abstract: The immunomodulatory effects of indomethacin (25 mg/day qid for 4 wk) were studied in 8 patients with acquired immune deficiency syndrome (AIDS)-related complex (ARC) and 8 patients meeting the Centers for Disease Control surveillance definition of AIDS. There was no significant effect of indomethacin treatment on mean OKT4/OKT8 ratios and mean mitogen-induced lymphocyte proliferative responses (measured as [3H]thymidine incorporation) in these patients. However, the OKT4/OKT8 ratio increased upon treatment with, and decreased after discontinuation of, indomethacin in three patients with ARC and one with AIDS. Similarly, indomethacin treatment was associated with improved lymphocyte proliferative responses to phytohemagglutinin in two patients with ARC and four patients with AIDS, to concanavalin A in one patient with ARC and four patients with AIDS, and to pokeweed mitogen in one patient with ARC and one patient with AIDS. These lymphocyte proliferative responses increased markedly after 28 days on indomethacin and decreased at 14 days following discontinuation. Clinically, three patients gained weight, and improvement was found in one with diarrhea, two with Candida infection, and one with lymphadenopathy. The improved mitogen-induced lymphocyte proliferative responses and clinical improvement observed in some of these 16 patients indicate that further trials appear warranted to establish immunologic effectiveness and clinical benefits. (15 Refs)

Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY/*IMMUNOLOGY AIDS-Related Complex/DRUG THERAPY/*IMMUNOLOGY Drug Evaluation Human Immunization Indomethacin/*IMMUNOLOGY/THERAPEUTIC USE Lymphocyte Transformation Male JOURNAL ARTICLE

880228
M8820382

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .